Table 1 Baseline demographic information, symptoms of COVID-19, comorbidity and laboratory findings in patients during admission
Variable | HD group (N = 122) | UD group (N = 116) | P value |
|---|---|---|---|
Male/female, n (%) | 83/39 (68/32) | 76/40 (66/34) | |
Age (year), median (IQR) | 63 (54.8–69) | 59 (54–68) | 0.655 |
Onset of symptom-to-hospitalization time, median (IQR) | 6 (6–8) | 7 (6–8) | 0.144 |
Fever (°F), median (IQR) | 101 (100–101) | 101 (100–101) | 0.306 |
Dry cough, n (%) | 122 (100) | 116 (100) | |
Weakness, n (%) | 122 (100) | 116 (100) | |
Shortness of breath, n (%) | 96 (78.7) | 94 (81) | 0.429 |
Anosmia, n (%) | 79 (64.8) | 88 (75.9) | 0.029 |
Diarrhea, n (%) | 68 (55.7) | 57 (49.1) | 0.001 |
Sore throat, n (%) | 62 (50.8) | 70 (60.3) | 0.001 |
Diabetes, n (%) | 95 (77.9) | 88 (75.9) | 0.392 |
Hypertension, n (%) | 86 (70.5) | 81 (69.8) | 0.166 |
CVD, n (%) | 55 (45.1) | 47 (40.5) | 0.001 |
Bronchial asthma, n (%) | 43 (35.2) | 36 (31) | 0.001 |
CKD, n (%) | 21 (17.2) | 23 (19.8) | 0.001 |
COPD, n (%) | 17 (13.9) | 14 (12.1) | 0.001 |
Obesity, n (%) | 15 (12.3) | 14 (12.1) | 0.001 |
PUD, n (%) | 11 (9) | 16 (13.8) | 0.001 |
CLD, n (%) | 6 (4.9) | 8 (6.9) | 0.001 |
Malignancy, n (%) | 3 (2.5) | 4 (3.4) | 0.001 |
PD, n (%) | 2 (1.6) | 1 (0.9) | 0.001 |
SpO2 (%), median (IQR) | 90 (88–90.3) | 90 (88–90) | 0.628 |
RSO, median (IQR) | 7 (4–11) | 7 (4–10) | 0.640 |
Respiratory rate, (breaths/min), median (IQR) | 25 (21–26) | 21 (19–25) | 0.001 |
Heart rate (beat/min), median (IQR) | 98 (85–106) | 90 (85–102) | 0.072 |
CRP (mg/L), median (IQR) | 179 (76.9–263.5) | 159 (44.5–231.4) | 0.199 |
Procalcitonin (ng/mL), median (IQR) | 1.04 (0.08–2.69) | 0.9 (0.12–1.26) | 0.001 |
WBC (K/μL), median (IQR) | 9.5 (6.4–12.4) | 9.2 (6.7–12.1) | 0.915 |
Neutrophils (%), median (IQR) | 86 (77.2–88.9) | 86.3 (78.6–90.2) | 0.110 |
Lymphocytes (%), median (IQR) | 14.3 (11.5–16.5) | 13.9 (10.8–16.4) | 0.141 |
Platelet (K/μL), median (IQR) | 188.5 (144.8–256) | 215 (150.7–295.8) | 0.327 |
D-dimer (mg /L FEU), median (IQR) | 5.2 (3.9–6.8) | 4.9 (2.6–6.3) | 0.392 |
IL-6 (pg/mL), median (IQR) | 47 (17.5–78) | 45 (10.5–75.7) | 0.153 |
Serum Ferritin (ng/mL), median (IQR) | 605 (478–786) | 641 (456–787.5) | 0.144 |
LDH ((U/L), median (IQR) | 489 (409–646.7) | 474 (408.5–593) | 0.088 |
Creatinine (mg/dL), median (IQR) | 1.1 (0.8–1.9) | 1.1 (0.7–1.7) | 0.122 |
ALT (U/L), median (IQR) | 58 (46–83) | 56 (40.7–75.8) | 0.485 |
AST (U/L), median (IQR) | 36.5 (29–48) | 35 (29–46) | 0.011 |
MEWS, median (IQR) | 3 (2–3) | 3 (2–3) | 0.001 |